ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Modulation of the unfolded protein response with a C-terminal fragment of MANF facilitates recovery in models of multiple sclerosis.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated MANF expression in β cells protects mice from streptozotocin-induced diabetes by attenuating islet stress and immunogenicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation in multiple sclerosis leads to chronic activation of a cellular stress mechanism, the unfolded protein response (UPR), which is thought to both exacerbate neuroinflammation and prevent regenerative tissue responses such as remyelination. The UPR-modulating protein MANF has shown great promise for attenuating chronic UPR activation and enhancing tissue regeneration in various disease models but does not reach the CNS when given peripherally. We utilized C-MANF, a C-terminal fragment of MANF, and showed that subcutaneous administration of C-MANF promoted motor function recovery and tissue regeneration in a mouse model of autoimmune demyelination. We demonstrated that C-MANF suppresses neuroinflammatory activation and facilitates the recovery of oligodendrocytes after demyelination, while reducing long-term activation of the UPR. Furthermore, we showed that C-MANF enhances myelination of primary OPCs in culture, that promotion of remyelination in cerebellar organotypic slice cultures is dependent on UPR-modulation, and that exogenously applied C-MANF suppresses chronic activation of all three UPR pathways in oligodendroglia. Finally, we showed that demyelination in MANF-deficient brains leads to extensive neuroinflammation and CNS degeneration, implicating UPR modulation by MANF as a key component in tissue responses to demyelination. Altogether, we show that UPR modulation with C-MANF is a promising new therapeutic approach for treating neuroinflammatory demyelination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.